Unigen continues to add to the extensive body of research surrounding Univestin, their innovative joint health ingredient, with new studies on the effects of the compound on reproduction in rats. Unigen performed 3 separate but related studies, labeled as Part-I through III. Each part addresses a different aspect of fertility, reproduction and development.
- Part-I: Effect of treatment at a stage of embryo to fetus development
- Part-II: Effect of treatment at the time of pregnancy (gestation) and the newborns (their development, behavior and sexual function)
- Part-III: Effect of treatment on maternal fertility and early embryonic development
Recently all three parts have been published in the Birth Defects Research Journal, Part B. The completion and publication of these studies adds to the robust safety package Unigen has been compiling on Univestin for over 10 years. All three studies showed no adverse effects on reproduction up to 1,000mg/kg dosing.
When asked about the research, Unigen’s CEO, Regan Miles answered, “Our commitment to continued research on Univestin, and all of our ingredients, is a big priority for Unigen. The publication of these studies furthers an already extensive safety profile we have been building.”
Abstracts for the publications can be found at the following links and more information on Univestin can be found at www.Univestin.com: